vs
Side-by-side financial comparison of Elme Communities (ELME) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $62.1M, roughly 1.4× Elme Communities). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 1.7%). Elme Communities produced more free cash flow last quarter ($7.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 2.7%).
Elme Communities is a publicly traded U.S. real estate investment trust that primarily owns, operates and develops high-quality multifamily residential communities. It focuses on key growth markets across the U.S. Mid-Atlantic and Southeast, offering affordable to mid-tier housing options for diverse renter groups.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ELME vs IOVA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $86.8M |
| Net Profit | $-123.5M | — |
| Gross Margin | 61.1% | 67.4% |
| Operating Margin | -183.3% | -84.7% |
| Net Margin | -198.9% | — |
| Revenue YoY | 1.7% | 17.7% |
| Net Profit YoY | -4058.7% | — |
| EPS (diluted) | $-1.40 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $86.8M | ||
| Q3 25 | $62.1M | $67.5M | ||
| Q2 25 | $62.1M | $60.0M | ||
| Q1 25 | $61.5M | $49.3M | ||
| Q4 24 | $61.3M | $73.7M | ||
| Q3 24 | $61.1M | $58.6M | ||
| Q2 24 | $60.1M | $31.1M | ||
| Q1 24 | $59.5M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-123.5M | $-91.3M | ||
| Q2 25 | $-3.6M | $-111.7M | ||
| Q1 25 | $-4.7M | $-116.2M | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $-3.0M | $-83.5M | ||
| Q2 24 | $-3.5M | $-97.1M | ||
| Q1 24 | $-3.6M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | 61.1% | 43.0% | ||
| Q2 25 | 63.5% | 5.5% | ||
| Q1 25 | 64.2% | -0.8% | ||
| Q4 24 | 62.9% | 68.7% | ||
| Q3 24 | 63.5% | 46.2% | ||
| Q2 24 | 63.4% | -0.8% | ||
| Q1 24 | 63.5% | — |
| Q4 25 | — | -84.7% | ||
| Q3 25 | -183.3% | -140.7% | ||
| Q2 25 | 9.6% | -189.8% | ||
| Q1 25 | 7.8% | -245.8% | ||
| Q4 24 | 10.4% | -117.5% | ||
| Q3 24 | 11.0% | -152.1% | ||
| Q2 24 | 9.8% | -327.6% | ||
| Q1 24 | 7.5% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | -198.9% | -135.3% | ||
| Q2 25 | -5.7% | -186.2% | ||
| Q1 25 | -7.6% | -235.5% | ||
| Q4 24 | -4.9% | — | ||
| Q3 24 | -4.9% | -142.7% | ||
| Q2 24 | -5.8% | -312.2% | ||
| Q1 24 | -6.1% | -15800.8% |
| Q4 25 | — | — | ||
| Q3 25 | $-1.40 | — | ||
| Q2 25 | $-0.04 | $-0.33 | ||
| Q1 25 | $-0.05 | $-0.36 | ||
| Q4 24 | $-0.04 | $-0.24 | ||
| Q3 24 | $-0.03 | $-0.28 | ||
| Q2 24 | $-0.04 | $-0.34 | ||
| Q1 24 | $-0.04 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $908.9M | $698.6M |
| Total Assets | $1.7B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | $7.1M | $300.8M | ||
| Q2 25 | $4.8M | $301.2M | ||
| Q1 25 | $6.4M | $359.7M | ||
| Q4 24 | $6.1M | $323.8M | ||
| Q3 24 | $4.8M | $397.5M | ||
| Q2 24 | $5.6M | $412.5M | ||
| Q1 24 | $4.2M | $356.2M |
| Q4 25 | — | $698.6M | ||
| Q3 25 | $908.9M | $702.3M | ||
| Q2 25 | $1.0B | $698.5M | ||
| Q1 25 | $1.1B | $767.9M | ||
| Q4 24 | $1.1B | $710.4M | ||
| Q3 24 | $1.1B | $773.5M | ||
| Q2 24 | $1.1B | $768.5M | ||
| Q1 24 | $1.1B | $680.0M |
| Q4 25 | — | $913.2M | ||
| Q3 25 | $1.7B | $904.9M | ||
| Q2 25 | $1.8B | $907.4M | ||
| Q1 25 | $1.8B | $966.7M | ||
| Q4 24 | $1.8B | $910.4M | ||
| Q3 24 | $1.9B | $991.1M | ||
| Q2 24 | $1.9B | $964.3M | ||
| Q1 24 | $1.9B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.9M | $-52.6M |
| Free Cash FlowOCF − Capex | $7.2M | $-61.9M |
| FCF MarginFCF / Revenue | 11.6% | -71.3% |
| Capex IntensityCapex / Revenue | 14.0% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $86.7M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-52.6M | ||
| Q3 25 | $15.9M | $-78.7M | ||
| Q2 25 | $29.8M | $-67.4M | ||
| Q1 25 | $16.2M | $-103.7M | ||
| Q4 24 | $95.2M | $-73.3M | ||
| Q3 24 | $20.7M | $-59.0M | ||
| Q2 24 | $28.9M | $-98.4M | ||
| Q1 24 | $21.2M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | $7.2M | $-89.5M | ||
| Q2 25 | $21.1M | $-74.9M | ||
| Q1 25 | $10.5M | $-109.9M | ||
| Q4 24 | $47.9M | $-77.5M | ||
| Q3 24 | $8.8M | $-61.3M | ||
| Q2 24 | $21.0M | $-98.9M | ||
| Q1 24 | $7.6M | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | 11.6% | -132.7% | ||
| Q2 25 | 34.1% | -124.9% | ||
| Q1 25 | 17.1% | -222.8% | ||
| Q4 24 | 78.1% | -105.1% | ||
| Q3 24 | 14.4% | -104.6% | ||
| Q2 24 | 34.9% | -317.9% | ||
| Q1 24 | 12.8% | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | 14.0% | 16.1% | ||
| Q2 25 | 14.0% | 12.4% | ||
| Q1 25 | 9.2% | 12.6% | ||
| Q4 24 | 77.4% | 5.7% | ||
| Q3 24 | 19.4% | 3.9% | ||
| Q2 24 | 13.1% | 1.4% | ||
| Q1 24 | 22.9% | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELME
| Residential Segment | $57.7M | 93% |
| Other | $4.4M | 7% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
